WEKO3
アイテム
A chemogenetic toolbox for primates
https://repo.qst.go.jp/records/74911
https://repo.qst.go.jp/records/7491163718afb-7f97-4813-a217-c550873ec227
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-02-25 | |||||
| タイトル | ||||||
| タイトル | A chemogenetic toolbox for primates | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
南本, 敬史
× 南本, 敬史× Minamimoto, Takafumi |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The chemogenetic technology, known as Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), affords reversible and remote control of the activity of a specific neuronal population expressing a designer receptor by systemic delivery of a biologically inert designer ligand. It has been widely used to modulate neuronal activity and subsequently alter behavior in rodent neuroscience studies. However, its application to non-human primates is limited. One of the technical difficulties in applying genetic manipulation techniques in general to monkeys is the delivery of transgene specifically into a target neuronal population and establishing stable expression throughout the experimental period. In addition, a technical problem of DREADDs is that the major DREADD agonist ligand, CNO, exhibits sluggish kinetics, metabolic liabilities, and potential for off-target effects, and therefore hampering selective and reliable chemogenetic manipulation. To overcome these problems/difficulties, we have developed a PET imaging technique to visualize expression of DREADD receptor in living monkeys, providing effective tools for non-invasive monitoring of gene expression for long-term behavioral studies (Nagai et al., 2016). We have also developed a new DREADD agonist, which has a high binding affinity, selectivity, and potency. Systemic delivery of this agonist activated DREADDs within minutes resulting in changing neuronal activity and behavioral alteration. Our set of tools—in vivo DREADD visualization and the new DREADD ligand—provide unique opportunity for selective, reliable and rapid chemogenetic manipulation of neuronal activity in non-human primates. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | New Directions in Systems Neuroscience | |||||
| 発表年月日 | ||||||
| 日付 | 2019-03-21 | |||||
| 日付タイプ | Issued | |||||
